Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L. & Habener, J. F. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc. Natl Acad. Sci. USA 84, 3434–3438 (1987).
Kreymann, B., Williams, G., Ghatei, M. A. & Bloom, S. R. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2, 1300–1304 (1987).
Drucker, D. J. & Holst, J. J. The expanding incretin universe: from basic biology to clinical translation. Diabetologia 66, 1765–1779 (2023).
Drucker, D. J. GLP-1-based therapies for diabetes, obesity and beyond. Nat. Rev. Drug Discov. 24, 631–650 (2025).
Deanfield, J. et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. Lancet 406, 2257–2268 (2025).
Gonzalez-Rellan, M. J. & Drucker, D. J. New molecules and indications for GLP-1 medicines. JAMA 334, 1231–1234 (2025).
Lingvay, I. et al. Once-weekly semaglutide 7.2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 13, 935–948 (2025).
Wharton, S. et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 13, 949–963 (2025).
Aroda, V. R. et al. High-dose semaglutide (up to 16 mg) in people with type 2 diabetes and overweight or obesity: a randomized, placebo-controlled, phase 2 trial. Diabetes Care 48, 905–913 (2025).
Frias, J. P. et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N. Engl. J. Med. 385, 503–515 (2021).
Aronne, L. J. et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N. Engl. J. Med. 393, 26–36 (2025).
Knop, F. K. et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 402, 705–719 (2023).
Wharton, S. et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. N. Engl. J. Med. 393, 1077–1087 (2025).
Overgaard, R. V., Hertz, C. L., Ingwersen, S. H., Navarria, A. & Drucker, D. J. Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes. Cell Rep. Med. 2, 100387 (2021).
Hannon, T. S. et al. Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 406, 1484–1496 (2025).
Ravussin, E. et al. Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation. Cell Metab. 37, 1060–1074 e1064 (2025).
Drucker, D. J. Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care 47, 1873–1888 (2024).
Borner, T. et al. GIP receptor agonism attenuates GLP-1 receptor agonist-induced nausea and emesis in preclinical models. Diabetes 70, 2545–2553 (2021).
Knop, F. K. et al. A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon-like peptide-1 receptor agonist therapy. Diabetes Obes. Metab. 26, 5474–5478 (2024).
Lee, M. M. Y. et al. Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials. Diabetes Care 48, 846–859 (2025).
Lilly Investors. Lilly’s Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease. https://investor.lilly.com/news-releases/news-release-details/lillys-mounjaro-tirzepatide-gipglp-1-dual-agonist-demonstrated/ (2025).
Gerstein, H. C. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394, 121–130 (2019).
Kosiborod, M. N. et al. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet 404, 949–961 (2024).
Packer, M. et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N. Engl. J. Med. 392, 427–437 (2025).
Lam, C. S. P. et al. Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT-MMO trial. Obesity 33, 1645–1656 (2025).
Lincoff, A. M. et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N. Engl. J. Med. 389, 2221–2232 (2023).
Sanyal, A. J. et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N. Engl. J. Med. 392, 2089–2099 (2025).
Perkovic, V. et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N. Engl. J. Med. 391, 109–121 (2024).
Bliddal, H. et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis. N. Engl. J. Med. 391, 1573–1583 (2024).
Bonaca, M. P. et al. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet 405, 1580–1593 (2025).
Rossing, P. et al. Effects of semaglutide with or without concomitant mineralocorticoid receptor antagonist use in participants with type 2 diabetes and chronic kidney disease: a FLOW trial prespecified secondary analysis. Diabetes Care 48, 1878–1887 (2025).
Mann, J. F. E. et al. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nat. Med. 30, 2849–2856 (2024).
Drucker, D. J. Prevention of cardiorenal complications in people with type 2 diabetes and obesity. Cell Metab. 36, 338–353 (2024).
Malhotra, A. et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N. Engl. J. Med. 391, 1193–1205 (2024).
Drucker, D. J. The benefits of GLP-1 drugs beyond obesity. Science 385, 258–260 (2024).
Jara, M. et al. Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis. Nat. Med. 31, 3128–3140 (2025).
Rasouli, N. et al. Benefit of semaglutide in symptomatic peripheral artery disease by baseline type 2 diabetes characteristics: insights from STRIDE, a randomized, placebo-controlled, double-blind trial. Diabetes Care 48, 1529–1535 (2025).
McGowan, B. M. et al. Efficacy and safety of once-weekly semaglutide 2.4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. Lancet Diabetes Endocrinol. 12, 631–642 (2024).
Jastreboff, A. M. et al. Tirzepatide for obesity treatment and diabetes prevention. N. Engl. J. Med. 392, 958–971 (2025).
Thomas, M. K. et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. J. Clin. Endocrinol. Metab. 106, 388–396 (2021).
Tang, H. et al. Glucagon-like peptide-1 receptor agonists and risk of Parkinson’s disease in patients with type 2 diabetes: a population-based cohort study. Mov. Disord. 39, 1960–1970 (2024).
Athauda, D. et al. Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet 390, 1664–1675 (2017).
Aviles-Olmos, I. et al. Exenatide and the treatment of patients with Parkinson’s disease. J. Clin. Invest. 123, 2730–2736 (2013).
McGarry, A. et al. Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 23, 37–45 (2024).
Meissner, W. C., Remy, P., Giordana, C., Maltete, D. & Derkinderen, P. Trial of lixisenatide in early Parkinson’s disease. N. Engl. J. Med. 390, 1176–1185 (2024).
Vijiaratnam, N. et al. Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson’s disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. Lancet 405, 627–636 (2025).
Cukierman-Yaffe, T. et al. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Lancet Neurol. 19, 582–590 (2020).
Koychev, I. et al. Inflammatory proteins associated with Alzheimer’s disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial. Alzheimers Res. Ther. 16, 212 (2024).
Maretty, L. et al. Proteomic changes upon treatment with semaglutide in individuals with obesity. Nat. Med. 31, 267–277 (2025).
Battini, V. et al. Comparing major and mild cognitive impairment risks in older type-2 diabetic patients: a Danish register-based study on dipeptidyl peptidase-4 inhibitors vs. glucagon-like peptide-1 analogues. J. Neurol. 271, 3417–3425 (2024).
Xie, Y., Choi, T. & Al-Aly, Z. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nat. Med. 31, 951–962 (2025).
Edison, P. et al. Evaluation of liraglutide in the treatment of Alzheimer’s disease. Alzheimers Dement. 17, e057848 (2021).
Cummings, J. L. et al. Evoke and Evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease. Alzheimers Res. Ther. 17, 14 (2025).
Novo Nordisk A/S: Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer’s disease progression; https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916462 (24 February 2025).
Svensson, P. A. et al. Non-alcohol substance use disorder after bariatric surgery in the prospective, controlled Swedish Obese Subjects study. Obesity 31, 2171–2177 (2023).
Lahteenvuo, M. et al. Repurposing semaglutide and liraglutide for alcohol use disorder. JAMA Psychiatry 82, 94–98 (2025).
Wang, W. et al. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nat. Commun. 15, 4548 (2024).
Wang, W. et al. Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study. Mol. Psychiatry 29, 2587–2598 (2024).
Farokhnia, M. et al. Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake. J. Clin. Invest. https://doi.org/10.1172/JCI188314 (2025).
Hendershot, C. S. et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry 82, 395–405 (2025).
Lengsfeld, S. et al. Effect of dulaglutide in promoting abstinence during smoking cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trial. EClinicalMedicine 57, 101865 (2023).
Probst, L. et al. Effects of dulaglutide on alcohol consumption during smoking cessation. JCI Insight 8, e170419 (2023).
Bruns Vi, N., Tressler, E. H., Vendruscolo, L. F., Leggio, L. & Farokhnia, M. IUPHAR review – glucagon-like peptide-1 (GLP-1) and substance use disorders: an emerging pharmacotherapeutic target. Pharm. Res. 207, 107312 (2024).
Dawed, A. Y. et al. Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials. Lancet Diabetes Endocrinol. 11, 33–41 (2023).
Willard, F. S. et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight 5, e140532 (2020).
German, J. et al. Association between plausible genetic factors and weight loss from GLP1-RA and bariatric surgery. Nat. Med. 31, 2269–2276 (2025).
Cifuentes, L. et al. Genetic and physiological insights into satiation variability predict responses to obesity treatment. Cell Metab. 37, 1655–1666 (2025).
Tzoulis, P. & Baldeweg, S. E. Semaglutide for weight loss: unanswered questions. Front. Endocrinol. 15, 1382814 (2024).
Ryan, D. H. et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat. Med. 30, 2049–2057 (2024).
Heni, M. et al. Heterogeneity in response to GLP-1 receptor agonists in type 2 diabetes in real-world clinical practice: insights from the DPV register – an IMI-SOPHIA study. Diabetologia 68, 1666–1673 (2025).
Squire, P., Naude, J., Zentner, A., Bittman, J. & Khan, N. Factors associated with weight loss response to GLP-1 analogues for obesity treatment: a retrospective cohort analysis. BMJ Open 15, e089477 (2025).
Baggio, L. L. et al. GLP-1 receptor expression within the human heart. Endocrinology 159, 1570–1584 (2018).
Hathaway, J. T. et al. Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmol. 142, 732–739 (2024).
Shor, R. et al. Glucagon-like peptide-1 receptor agonists and risk of neovascular age-related macular degeneration. JAMA Ophthalmol. 143, 587–594 (2025).
Imbroane, M. R., LeMoine, F. & Nau, C. T. Preconception glucagon-like peptide-1 receptor agonist use associated with decreased risk of adverse obstetrical outcomes. Am. J. Obstet. Gynecol. 233, 116.e1–116.e7 (2025).
Hanif, M. et al. Efficacy and safety of glucagon-like peptide-1 receptor agonist use during the first trimester in pregnant women with type 2 diabetes. Am. J. Cardiol. 246, 10–13 (2025).
Dao, K. et al. Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services. BMJ Open 14, e083550 (2024).
Kindel, T. L. et al. Multi-society clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. Surg. Endosc. 39, 180–183 (2025).
Dixit, A. A., Bateman, B. T., Hawn, M. T., Odden, M. C. & Sun, E. C. Preoperative GLP-1 receptor agonist use and risk of postoperative respiratory complications. JAMA 331, 1672–1673 (2024).
Wadden, T. A. et al. Psychiatric safety of semaglutide for weight management in people without known major psychopathology: post hoc analysis of the STEP 1, 2, 3, and 5 trials. JAMA Intern. Med. 184, 1290–1300 (2024).
Ueda, P. et al. GLP-1 receptor agonist use and risk of suicide death. JAMA Intern. Med. 184, 1301–1312 (2024).
Wang, W. et al. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat. Med. 30, 168–176 (2024).
Hurtado, I., Robles, C., Peiro, S., Garcia-Sempere, A. & Sanfelix-Gimeno, G. Association of glucagon-like peptide-1 receptor agonists with suicidal ideation and self-injury in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study. Diabetologia 67, 2471–2480 (2024).
Shapiro, S. B. et al. Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study. BMJ 388, e080679 (2025).
Jastreboff, A. M. et al. Triple-hormone-receptor agonist retatrutide for obesity – a phase 2 trial. N. Engl. J. Med. 389, 514–526 (2023).
Conte, C., Hall, K. D. & Klein, S. Is weight loss-induced muscle mass loss clinically relevant? JAMA 332, 9–10 (2024).
Coskun, T. et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol. 13, 674–684 (2025).
Lundgren, J. R. et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N. Engl. J. Med. 384, 1719–1730 (2021).
Scott Butsch, W. et al. Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: a retrospective observational study. Obes. Pillars 15, 100186 (2025).
Frias, J. P. et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet 402, 720–730 (2023).
Wharton, S. et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N. Engl. J. Med 389, 877–888 (2023).
Enebo, L. B. et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet 397, 1736–1748 (2021).
Rosenstock, J. et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet 402, 529–544 (2023).
Kizilkaya, H. S. et al. Characterization of genetic variants of GIPR reveals a contribution of beta-arrestin to metabolic phenotypes. Nat. Metab. 6, 1268–1281 (2024).
Veniant, M. M. et al. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat. Metab. 6, 290–303 (2024).
le Roux, C. W. et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 12, 162–173 (2024).
Davies, M. J. et al. Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes. N. Engl. J. Med. 393, 648–659 (2025).
Garvey, W. T. et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. N. Engl. J. Med. 393, 635–647 (2025).
Wean, J. et al. Specific loss of GIPR signaling in GABAergic neurons enhances GLP-1R agonist-induced body weight loss. Mol. Metab. 95, 102074 (2025).
Gutgesell, R. M. et al. GIPR agonism and antagonism decrease body weight and food intake via different mechanisms in male mice. Nat. Metab. 7, 1282–1298 (2025).
Liu, C. M. et al. GIPR-Ab/GLP-1 peptide-antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice. Nat. Metab. 7, 1266–1281 (2025).
Braca, S. et al. Effectiveness and tolerability of liraglutide as add-on treatment in patients with obesity and high-frequency or chronic migraine: a prospective pilot study. Headache 65, 1831–1838 (2025).
Dahl, K. et al. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. Lancet 406, 149–162 (2025).
Jastreboff, A. M. et al. Once-monthly maridebart cafraglutide for the treatment of obesity – a phase 2 trial. N. Engl. J. Med. 393, 843–857 (2025).
Rosenstock, J. et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. N. Engl. J. Med. 393, 1065–1076 (2025).
McGuire, D. K. et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N. Engl. J. Med. 392, 2001–2012 (2025).
Tamborlane, W. V. et al. Liraglutide in children and adolescents with type 2 diabetes. N. Engl. J. Med. 381, 637–646 (2019).
Tamborlane, W. V. et al. Once-weekly exenatide in youth with type 2 diabetes. Diabetes Care 45, 1833–1840 (2022).
Arslanian, S. A. et al. Once-weekly dulaglutide for the treatment of youths with type 2 diabetes. N. Engl. J. Med. 387, 433–443 (2022).
Kelly, A. S. et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N. Engl. J. Med. 382, 2117–2128 (2020).
Weghuber, D. et al. Once-weekly semaglutide in adolescents with obesity. N. Engl. J. Med. 387, 2245–2257 (2022).
Mathieu, C. et al. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial. Diabetes Care 39, 1702–1710 (2016).
Shah, V. N. et al. Semaglutide in adults with type 1 diabetes and obesity. NEJM Evid. 4, EVIDoa2500173 (2025).
Pasqua, M. R. et al. Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial. Nat. Med. 31, 1239–1245 (2025).
Dejgaard, T. F. et al. Liraglutide enhances insulin secretion and prolongs the remission period in adults with newly diagnosed type 1 diabetes (the NewLira study): a randomized, double-blind, placebo-controlled trial. Diabetes Obes. Metab. 26, 4905–4915 (2024).